PTSD drug trial halted early: could brexanolone ease trauma?
NCT ID NCT05254405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a 24-hour IV infusion of brexanolone in 10 adult women with PTSD from non-military trauma. The goal was to see if it could reduce PTSD symptoms and lead to remission by 12 weeks. The trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas at Austin Dell Medical School
Austin, Texas, 78712, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a surgeon's mental health impact your surgery outcome?
- Zapping the brain with microcurrents may curb cravings — a trial puts it to the test
- Can a pressurized oxygen chamber keep brain benefits alive months later?
- A prescription app takes on PTSD: can digital therapy replace the couch?
- A targeted talk therapy aims to quiet the echoes of trauma
- Can a therapy that tackles both PTSD and everyday stress help those most at risk?